TNGX
Tango Therapeutics Inc

711
Mkt Cap
$1.5B
Volume
1.85M
52W High
$13.60
52W Low
$1.03
PE Ratio
-12.15
TNGX Fundamentals
Price
$11.14
Prev Close
$11.40
Open
$11.11
50D MA
$11.17
Beta
1.17
Avg. Volume
3.19M
EPS (Annual)
-$1.19
P/B
7.77
Rev/Employee
$271,412.90
$116.09
Loading...
Loading...
News
all
press releases
Tango Therapeutics (NASDAQ:TNGX) Insider Adam Crystal Sells 54,345 Shares
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) insider Adam Crystal sold 54,345 shares of the stock in a transaction that occurred on Wednesday, February 25th. The stock was sold at an...
MarketBeat·1d ago
News Placeholder
More News
News Placeholder
Adam Crystal Sells 54,345 Shares of Tango Therapeutics (NASDAQ:TNGX) Stock
Tango Therapeutics, Inc. (NASDAQ:TNGX - Get Free Report) insider Adam Crystal sold 54,345 shares of the company's stock in a transaction dated Wednesday, February 25th. The stock was sold at an...
MarketBeat·2d ago
News Placeholder
Tango Therapeutics (NASDAQ:TNGX) Trading Down 10.4% - Here's What Happened
Tango Therapeutics (NASDAQ:TNGX) Trading Down 10.4% - Time to Sell...
MarketBeat·3d ago
News Placeholder
RVMD Reports Wider-Than-Expected Q4 Loss, Issues 2026 Expense View
Revolution Medicines posts a wider-than-expected Q4 loss and sees 2026 operating expenses of $1.6B-$1.7B as it advances late-stage RAS pipeline studies.
Zacks·3d ago
News Placeholder
Tango Therapeutics (NASDAQ:TNGX) Hits New 1-Year High - Here's Why
Tango Therapeutics (NASDAQ:TNGX) Hits New 12-Month High - Time to Buy...
MarketBeat·5d ago
News Placeholder
Tango Therapeutics (NASDAQ:TNGX) Trading Up 8.8% - Should You Buy?
Tango Therapeutics (NASDAQ:TNGX) Trading Up 8.8% - Here's What Happened...
MarketBeat·6d ago
News Placeholder
Tango Therapeutics (NASDAQ:TNGX) Coverage Initiated at Mizuho
Mizuho initiated coverage on shares of Tango Therapeutics in a research note on Monday. They issued an "outperform" rating and a $19.00 target price for the company...
MarketBeat·6d ago
News Placeholder
Tango Therapeutics (TNGX) to Release Earnings on Thursday
Tango Therapeutics (NASDAQ:TNGX) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...
MarketBeat·10d ago
News Placeholder
Readystate Asset Management LP Trims Holdings in Tango Therapeutics, Inc. $TNGX
Readystate Asset Management LP reduced its stake in Tango Therapeutics, Inc. (NASDAQ:TNGX - Free Report) by 41.4% in the 3rd quarter, according to the company in its most recent filing with the...
MarketBeat·11d ago
News Placeholder
Tango Therapeutics CEO Teases Pivotal Vopimetostat Trial, RAS Combo Data at Guggenheim Chat
Tango Therapeutics (NASDAQ:TNGX) is preparing to move further into late-stage development for its PRMT5 inhibitor vopimetostat, newly appointed CEO Malte Peters said during a Guggenheim fireside...
MarketBeat·14d ago
<
1
2
...
>

Latest TNGX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.